The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of a study drug for non-alcoholic steatohepatitis (NASH), a type of liver disease. This study will look at the effects of the study drug at different doses and when taken with and without food.
NASH is a serious, progressive liver disease caused by a buildup of fat in the liver, resulting in inflammation, cell damage, and scarring of the liver. NASH significantly increases morbidity and the risk of complications like heart attack or stroke. There are currently no therapeutic options approved for NASH, but researchers are working hard to develop treatments for the disease.
Who may participate
By volunteering in clinical research, you can help change the lives of patients around the world.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**females must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 16 overnights, broken up into 4 separate stays of 4 nights each. On the morning after each admission, you will receive either a single dose of the study drug or a placebo (no active ingredient) for a maximum of up to 4 doses throughout the study. Whether you receive the study drug or placebo is chosen at random. All doses are given as a liquid to swallow and may be given with or without food.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
Required overnight stays
4 overnights per admission for 4 admissions
Long-term follow up
1 visit + 1 phone call
How long is this study?
About 72-79 days
Up to $6,480-6,585 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you. Please note: volunteers completing this form must be able to read and speak English at an 8th grade level.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984. We apologize, our representatives cannot take calls in languages other than English or Japanese at this time.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.